Verónica Alonso-Pérez

The CRISPR/Cas9 system efficiently reverts the tumorigenic ability of <i>BCR/ABL in vitro</i> and in a xenograft model of chronic myeloid leukemia

Ignacio García‐Tuñón, María Hernández‐Sánchez, José Luis Ordóñez et al. · Oncotarget · 2017 · 39 citations · Full text

Apoptosis, Immunology, Cell Death +20

CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition

Miguel Quijada‐Álamo, María Hernández‐Sánchez, Verónica Alonso-Pérez et al. · Leukemia · 2020 · 35 citations · Full text

Splice donor site sgRNAs enhance CRISPR/Cas9-mediated knockout efficiency

Ignacio García‐Tuñón, Verónica Alonso-Pérez, Elena Vuelta et al. · PLoS ONE · 2019 · 28 citations · Full text

Crispr System, Natural Sciences, Genetics +11

ETV6/RUNX1 Fusion Gene Abrogation Decreases the Oncogenicity of Tumour Cells in a Preclinical Model of Acute Lymphoblastic Leukaemia

Adrián Montaño, José Luis Ordóñez, Verónica Alonso-Pérez et al. · Cells · 2020 · 19 citations · Full text

Biological significance of monoallelic and biallelic BIRC3 loss in del(11q) chronic lymphocytic leukemia progression

Miguel Quijada‐Álamo, María Hernández‐Sánchez, Ana‐Eugenia Rodríguez‐Vicente et al. · Blood Cancer Journal · 2021 · 19 citations · Full text